FinnCap Reiterates Buy Rating for Motif Bio PLC (MTFB)
Motif Bio PLC (LON:MTFB)‘s stock had its “buy” rating reaffirmed by stock analysts at FinnCap in a research note issued on Wednesday. They currently have a GBX 100 ($1.33) target price on the stock. FinnCap’s price target would indicate a potential upside of 172.11% from the stock’s previous close.
A number of other equities analysts have also recently commented on MTFB. Beaufort Securities restated a “speculative buy” rating and set a GBX 110 ($1.46) target price on shares of Motif Bio PLC in a report on Monday. Northland Securities reaffirmed a “buy” rating on shares of Motif Bio PLC in a research report on Friday, September 29th.
Motif Bio PLC (LON:MTFB) opened at 36.75 on Wednesday. Motif Bio PLC has a 52-week low of GBX 21.44 and a 52-week high of GBX 53.50. The stock’s 50 day moving average price is GBX 29.51 and its 200-day moving average price is GBX 30.31. The company’s market cap is GBX 96.61 million.
Motif Bio PLC Company Profile
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Ratings for Motif Bio PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.